FDA approves second brain imaging drug to help evaluate patients for Alzheimer's disease, dementia

The U.S. Food and Drug Administration has approved Vizamyl (flutemetamol F 18 injection), a radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer’s disease (AD) and dementia. Dementia is associated with diminishing brain functions such as memory, judgment, language Read & Research Alzheimer’s More

Leave a Reply